Can a heart drug mend damage from breast cancer therapy?

NCT ID NCT05806138

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study tests whether adding vericiguat to standard heart failure care can improve heart function in people with breast cancer who developed heart problems after cancer treatment. Participants will be randomly assigned to receive either vericiguat plus usual care or usual care alone. The main goal is to see if vericiguat improves exercise capacity, measured by a cardiopulmonary exercise test, after six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vericiguat
What this could lead to: If effective, vericiguat could become a new treatment to help breast cancer survivors recover heart function weakened by cancer therapy.
What could go wrong: This is a small, early-stage trial, so results may not apply broadly. Vericiguat may cause side effects or may not improve heart function more than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CARDIAC DYSFUNCTION

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.